3-Methylbenzoic acid → N-[6-(1H-indol-4-yl)-1H-indazol-4-yl]-3-methylbenzamide

3-Methylbenzoic acid (60 mg, 0.44 mmol) was treated with HATU (168 mg, 0.44 mmol) in DMF (0.750 mL) and DIPEA (0.15 mL, 0.86 mmol). The mixture was shaken for five minutes prior to treatment with 6-(1H-indol-4-yl)-1H-indazol-4-amine (50 mg, 0.2 mmol) in DMF (0.350 mL) and was then left to stand at room temperature for 16 hrs. Solvent was removed in vacuo and the product re-dissolved in chloroform (0.3 mL) prior to application on to a pre-conditioned (methanol then chloroform) NH2 cartridge (1 g). Product was eluted after 2 hr with ethyl acetate/methanol (1:1, 3.2 mL), and concentrated under a stream of nitrogen using blow down apparatus. Purification by MDAP (Method C) afforded the title compound.

1. waitto stand at room temperature for 16 hrs
2. customSolvent was removed in vacuo
3. dissolutionthe product re-dissolved in chloroform (0.3 mL)
4. washProduct was eluted after 2 hr with ethyl acetate/methanol (1:1, 3.2 mL)
5. concentrationconcentrated under a stream of nitrogen using blow down apparatus
6. customPurification by MDAP (Method C)

ORD-Eintrag

ord-0f9fc47f8c304901be6b41edb9604a18

Quelldatensatz

uspto-grants-2013_09

DOI

10.6084/m9.figshare.5104873.v1

Patentnummer

US08536169B2